Literature DB >> 25248644

[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice.

Thomas Krohn1, Frederik A Verburg, Thomas Pufe, Winfried Neuhuber, Andreas Vogg, Alexander Heinzel, Felix M Mottaghy, Florian F Behrendt.   

Abstract

PURPOSE: To determine the frequency of seemingly pathological retroperitoneal uptake in the location of the coeliac ganglia in patients undergoing [(68)Ga]PSMA-HBED PET/CT.
METHODS: The study included 85 men with prostate cancer referred for [(68)Ga]PSMA-HBED PET/CT. The PET/CT scans were evaluated for the local finding in the prostate and the presence of lymph node metastases, distant metastases and coeliac ganglia. The corresponding standardized uptake values (SUV) were determined. SUVmax to background uptake (gluteal muscle SUVmean) ratios were calculated for the ganglia and lymph node metastases. Immunohistochemistry was performed on the ganglia.
RESULTS: In 76 of the 85 patients (89.4%) at least one ganglion with tracer uptake was found. For the ganglia, SUVmax and SUVmax to background SUVmean ratios were 2.97 ± 0.88 and 7.98 ± 2.84 (range 1.57-6.38 and 2.83-30.6), respectively, and 82.8% of all ganglia showed an uptake ratio of >5.0. For lymph node metastases, SUVmax and SUVmax to background SUVmean ratios were 8.5 ± 7.0 and 23.31 ± 22.23 (range 2.06-35.9 and 5.25-115.8), respectively. In 35 patients (41.2%), no lymph node metastases were found but tracer uptake was seen in the ganglia. Immunohistochemistry confirmed strong PSMA expression in the ganglia.
CONCLUSION: Coeliac ganglia show a relevant [(68)Ga]PSMA-HBED uptake in most patients and may mimic lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248644     DOI: 10.1007/s00259-014-2915-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  11 in total

1.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  Multi-detector row computed tomographic appearance of celiac ganglia.

Authors:  Zhen J Wang; Emily M Webb; Antonio C Westphalen; Fergus V Coakley; Benjamin M Yeh
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

3.  Neural ganglia visualized by endoscopic ultrasound.

Authors:  Michael Levy; Elizabeth Rajan; Gary Keeney; Joel G Fletcher; Mark Topazian
Journal:  Am J Gastroenterol       Date:  2006-06-16       Impact factor: 10.864

4.  Depiction of celiac ganglia on positron emission tomography and computed tomography in patients with lung cancer.

Authors:  Seyed Mahdi Abtahi; Azadeh Elmi; Sandeep S Hedgire; Yuen Chi Ho; Sarvenaz Pourjabbar; Sarabjeet Singh; Mannudeep Kalra; Mukesh Harisinghani
Journal:  Clin Imaging       Date:  2014-01-06       Impact factor: 1.605

5.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

6.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

7.  The human celiac ganglion and its splanchnic nerves.

Authors:  Z Paz; A Rosen
Journal:  Acta Anat (Basel)       Date:  1989

8.  Detection of celiac ganglia with radial scanning endoscopic ultrasonography.

Authors:  Tae-In Ha; Gwang-Ha Kim; Dae-Hwan Kang; Geun-Am Song; Suk Kim; Jun-Woo Lee
Journal:  Korean J Intern Med       Date:  2008-03       Impact factor: 2.884

9.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

10.  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

View more
  59 in total

1.  Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

Authors:  Francisco Osvaldo García-Pérez; Jenny Davanzo; Sergio López-Buenrostro; Clara Santos-Cuevas; Guillermina Ferro-Flores; Miguel A Jímenez-Ríos; Anna Scavuzzo; Zael Santana-Ríos; Sevastián Medina-Ornelas
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors:  Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

3.  68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Authors:  Maria Vinsensia; Peter L Chyoke; Boris Hadaschik; Tim Holland-Letz; Jan Moltz; Klaus Kopka; Isabel Rauscher; Walter Mier; Markus Schwaiger; Uwe Haberkorn; Tobias Mauer; Clemens Kratochwil; Matthias Eiber; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-21       Impact factor: 10.057

4.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 5.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

6.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI.

Authors:  Liesbeth De Coster; Raf Sciot; Wouter Everaerts; Olivier Gheysens; Raf Verscuren; Christophe M Deroose; Steven Pans; Koen Van Laere; Karolien E Goffin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

7.  The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Authors:  Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

8.  Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.

Authors:  Stefano Fanti; Silvia Minozzi; Joshua James Morigi; Frederik Giesel; Francesco Ceci; Christian Uprimny; Michael S Hofman; Matthias Eiber; Sarah Schwarzenbock; Paolo Castellucci; Cristina Bellisario; Stéphane Chauvie; Fabrizio Bergesio; Louise Emmett; Uwe Haberkorn; Irene Virgolini; Markus Schwaiger; Rodney J Hicks; Bernd J Krause; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-23       Impact factor: 9.236

9.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 10.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.